Europe Medical Cannabis Market Forecast by 2033

Market Size in 2024: USD 2,586.1 Million
Market Forecast in 2033: USD 12,652.9 Million
Market Growth Rate 2025-2033: 18.33%

The Europe medical cannabis market is projected to expand more than fourfold over the next decade. Starting from a 2024 valuation of USD 2,586.1 million, revenue is expected to reach USD 12,652.9 million by 2033, reflecting a robust compound annual growth rate of 18.33%. Rising patient demand, widening reimbursement schemes, and a steady stream of product approvals underpin this rapid ascent.

Europe Medical Cannabis Market Growth Drivers

Progressive Legalization Across the Region

Governments are making rules much faster than before. In April 2024, Germany allowed adults to possess and grow small amounts of cannabis and made it easier for people to get medical cannabis. Italy raised how much of cannabis it can bring in by 30% for the year 2025. Spain’s Agency for Medicines and Medical Devices started a test program to reimburse people who use cannabinoid therapy. These changes mean there will be more people who can get help, new ways for producers to work, and a clear sign for investors that Europe is ready to grow this business.

Expanding Clinical Validation & Evidence-Based

More people trust the science behind this. The European Medicines Agency gave orphan-drug status to a CBD formula in 2024. This is for tuberous sclerosis. After this, national health institutes decided to give more than EUR 50 million for next studies. At the same time, Denmark and the Netherlands are running new tests to see how micro-dosed THC can help with diabetic nerve pain. Biotech companies in Portugal are using EU Recovery Funds to grow their GMP extraction sites. Every time there is a new peer-reviewed report, doctors trust these treatments more. This also means they are used for more cases and doctors write even more prescriptions.

Next-Gen Grow and Delivery Methods

These new ways to grow and deliver are changing the game. They help people get the products they want in a better, faster way. It makes things easier for everyone. The use of smart tools and fresh ideas lets us do more, save time, and give people what they need. Europe’s growers are moving forward with new high-tech ways of farming. There is a 25-hectare glasshouse near Dresden. It uses AI and special cameras to adjust the amounts of cannabinoids as it happens. This change has helped to double the amount the plants grow in every square meter. At the same time, makers now offer smart inhalers. There are also sub-lingual films. These help people get just the right amount of medicine they need. That is very important for kids with epilepsy. It's also needed for older cancer patients. The costs to make these products are now lower. Each batch comes out more the same every time. People also say the experience is better than before. All this is helping more people use it. It also helps Europe send these products out to other countries.

Request your complimentary sample of the full report here: https://www.imarcgroup.com/Europe-Medical-Cannabis-Market/requestsample

Europe Medical Cannabis Market Segmentation

Analysis by Species

• Indica
• Sativa
• Hybrid

Analysis by Derivative

• Cannabidiol (CBD)
• Tetrahydrocannabinol (THC)
• Others

Analysis by Application

• Cancer
• Arthritis
• Migraine
• Epilepsy
• Others

Analysis by End Use

• Pharmaceutical Industry
• Research and Development Centers
• Others

Analysis by Route of Administration

• Oral Solutions and Capsules
• Smoking
• Vaporizers
• Topicals
• Others

Analysis by Country

• Germany
• France
• United Kingdom
• Italy
• Spain
• Others

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Europe Medical Cannabis Market News:

• May 2025: Curaleaf International secures EU medical-device approval for a portable liquid inhaler, enabling precise, on-the-go dosing of medical cannabis formulations.
• April 2025: Aurora Cannabis launches inhalable resin cartridges in the UK under the Sourdough and Electric Honeydew strains, targeting rapid onset for breakthrough pain episodes.
• March 2025: Tilray Medical introduces “Tilray Craft,” a premium flower line in Germany, featuring high-THC, terpene-rich genetics designed for experienced patients.
• February 2025: Canopy Growth debuts its Tweed medical brand in Germany, sourcing EU-GMP flower from Portuguese partner Gro-Vida to meet local-content demand.
• January 2025: Aurora ships its first Germany-grown IndiMed flower from its Leuna facility, reducing import dependency and cutting delivery lead times for pharmacies.

 Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.